Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy

Inhibitors of the receptor tyrosine kinase c-MET are currently used in the clinic to target oncogenic signaling in tumor cells. We found that concomitant c-MET inhibition promoted adoptive T cell transfer and checkpoint immunotherapies in murine cancer models by increasing effector T cell infiltrati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Glodde, Nicole Erika (VerfasserIn) , Gebhardt, Christoffer (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: October 17, 2017
In: Immunity
Year: 2017, Jahrgang: 47, Heft: 4, Pages: 789-802.e9
ISSN:1097-4180
DOI:10.1016/j.immuni.2017.09.012
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/j.immuni.2017.09.012
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1074761317304235
Volltext
Verfasserangaben:Nicole Glodde, Tobias Bald, Debby van den Boorn-Konijnenberg, Kyohei Nakamura, Jake S. O’Donnell, Sabrina Szczepanski, Maria Brandes, Sarah Eickhoff, Indrajit Das, Naveen Shridhar, Daniel Hinze, Meri Rogava, Tetje C. van der Sluis, Janne J. Ruotsalainen, Evelyn Gaffal, Jennifer Landsberg, Kerstin U. Ludwig, Christoph Wilhelm, Monika Riek-Burchardt, Andreas J. Müller, Christoffer Gebhardt, Richard A. Scolyer, Georgina V. Long, Viktor Janzen, Michele W.L. Teng, Wolfgang Kastenmüller, Massimiliano Mazzone, Mark J. Smyth, Thomas Tüting, and Michael Hölzel

MARC

LEADER 00000caa a2200000 c 4500
001 1582723540
003 DE-627
005 20240316100539.0
007 cr uuu---uuuuu
008 181108s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.immuni.2017.09.012  |2 doi 
035 |a (DE-627)1582723540 
035 |a (DE-576)512723540 
035 |a (DE-599)BSZ512723540 
035 |a (OCoLC)1341022591 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Glodde, Nicole Erika  |e VerfasserIn  |0 (DE-588)1130252094  |0 (DE-627)884575047  |0 (DE-576)486688097  |4 aut 
245 1 0 |a Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy  |c Nicole Glodde, Tobias Bald, Debby van den Boorn-Konijnenberg, Kyohei Nakamura, Jake S. O’Donnell, Sabrina Szczepanski, Maria Brandes, Sarah Eickhoff, Indrajit Das, Naveen Shridhar, Daniel Hinze, Meri Rogava, Tetje C. van der Sluis, Janne J. Ruotsalainen, Evelyn Gaffal, Jennifer Landsberg, Kerstin U. Ludwig, Christoph Wilhelm, Monika Riek-Burchardt, Andreas J. Müller, Christoffer Gebhardt, Richard A. Scolyer, Georgina V. Long, Viktor Janzen, Michele W.L. Teng, Wolfgang Kastenmüller, Massimiliano Mazzone, Mark J. Smyth, Thomas Tüting, and Michael Hölzel 
264 1 |c October 17, 2017 
300 |a 23 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 08.11.2018 
520 |a Inhibitors of the receptor tyrosine kinase c-MET are currently used in the clinic to target oncogenic signaling in tumor cells. We found that concomitant c-MET inhibition promoted adoptive T cell transfer and checkpoint immunotherapies in murine cancer models by increasing effector T cell infiltration in tumors. This therapeutic effect was independent of tumor cell-intrinsic c-MET dependence. Mechanistically, c-MET inhibition impaired the reactive mobilization and recruitment of neutrophils into tumors and draining lymph nodes in response to cytotoxic immunotherapies. In the absence of c-MET inhibition, neutrophils recruited to T cell-inflamed microenvironments rapidly acquired immunosuppressive properties, restraining T cell expansion and effector functions. In cancer patients, high serum levels of the c-MET ligand HGF correlated with increasing neutrophil counts and poor responses to checkpoint blockade therapies. Our findings reveal a role for the HGF/c-MET pathway in neutrophil recruitment and function and suggest that c-MET inhibitor co-treatment may improve responses to cancer immunotherapy in settings beyond c-MET-dependent tumors. 
650 4 |a bone marrow 
650 4 |a c-MET 
650 4 |a cancer immunotherapy 
650 4 |a HGF 
650 4 |a lymph node 
650 4 |a melanoma 
650 4 |a neutrophils 
650 4 |a plasticity 
650 4 |a T cells 
650 4 |a therapy resistance 
700 1 |a Gebhardt, Christoffer  |d 1976-  |e VerfasserIn  |0 (DE-588)13051151X  |0 (DE-627)503031666  |0 (DE-576)298240289  |4 aut 
773 0 8 |i Enthalten in  |t Immunity  |d [Cambridge, Mass.] : Cell Press, 1994  |g 47(2017), 4, Seite 789-802.e9  |h Online-Ressource  |w (DE-627)320416240  |w (DE-600)2001966-X  |w (DE-576)090881419  |x 1097-4180  |7 nnas  |a Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy 
773 1 8 |g volume:47  |g year:2017  |g number:4  |g pages:789-802.e9  |g extent:23  |a Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy 
856 4 0 |u http://dx.doi.org/10.1016/j.immuni.2017.09.012  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S1074761317304235  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181108 
993 |a Article 
994 |a 2017 
998 |g 13051151X  |a Gebhardt, Christoffer  |m 13051151X:Gebhardt, Christoffer  |d 60000  |d 61900  |e 60000PG13051151X  |e 61900PG13051151X  |k 0/60000/  |k 1/60000/61900/  |p 21 
999 |a KXP-PPN1582723540  |e 3030668851 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"23 S."}],"person":[{"given":"Nicole Erika","role":"aut","display":"Glodde, Nicole Erika","family":"Glodde","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Gebhardt, Christoffer","given":"Christoffer","family":"Gebhardt","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["Nicole Glodde, Tobias Bald, Debby van den Boorn-Konijnenberg, Kyohei Nakamura, Jake S. O’Donnell, Sabrina Szczepanski, Maria Brandes, Sarah Eickhoff, Indrajit Das, Naveen Shridhar, Daniel Hinze, Meri Rogava, Tetje C. van der Sluis, Janne J. Ruotsalainen, Evelyn Gaffal, Jennifer Landsberg, Kerstin U. Ludwig, Christoph Wilhelm, Monika Riek-Burchardt, Andreas J. Müller, Christoffer Gebhardt, Richard A. Scolyer, Georgina V. Long, Viktor Janzen, Michele W.L. Teng, Wolfgang Kastenmüller, Massimiliano Mazzone, Mark J. Smyth, Thomas Tüting, and Michael Hölzel"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"part":{"pages":"789-802.e9","year":"2017","extent":"23","issue":"4","volume":"47","text":"47(2017), 4, Seite 789-802.e9"},"origin":[{"publisher":"Cell Press ; Elsevier","publisherPlace":"[Cambridge, Mass.] ; New York, NY","dateIssuedKey":"1994","dateIssuedDisp":"1994-"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"id":{"issn":["1097-4180"],"zdb":["2001966-X"],"eki":["320416240"]},"title":[{"title":"Immunity","title_sort":"Immunity"}],"note":["Gesehen am 11.03.24"],"disp":"Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapyImmunity","pubHistory":["1.1994 -"],"recId":"320416240"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"October 17, 2017","dateIssuedKey":"2017"}],"language":["eng"],"recId":"1582723540","id":{"doi":["10.1016/j.immuni.2017.09.012"],"eki":["1582723540"]},"title":[{"title":"Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy","title_sort":"Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy"}],"note":["Gesehen am 08.11.2018"]} 
SRT |a GLODDENICOREACTIVENE1720